Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications.
Radha RaniNeha RainaAjay SharmaPramod KumarHardeep Singh TulliMadhu GuptaPublished in: Naunyn-Schmiedeberg's archives of pharmacology (2023)
Rheumatoid arthritis is a hyperactive immune disorder that results in severe inflammation in synovial joints, cartilage, and bone deterioration, resulting in immobilization of joints. Traditional approaches for the treatment of rheumatoid arthritis are associated with some limiting factors such as suboptimal patient compliance, inability to control the progression of disorder, and safety concerns. Therefore, innovative drug delivery carriers for efficient therapeutic delivery at inflamed synovial sites with better safety assessment are urgently needed to address these issues. From this perspective, nanotechnology is an outstanding alternative to traditional drug delivery approaches, and it has shown great promise in developing novel carriers to treat rheumatoid arthritis. Considering the current research and future application of nanocarriers, it is believed that nanocarriers can be a crucial element in rheumatoid arthritis treatment. This paper covers all currently available pathophysiological aspects of rheumatoid arthritis and treatment options. Future research for the reduction of synovial inflammation should focus on developing multifunction nanoparticles capable of delivering therapeutic agents with improved safety, efficacy, and cost-effectiveness to be commercialized.
Keyphrases
- rheumatoid arthritis
- drug delivery
- disease activity
- ankylosing spondylitis
- interstitial lung disease
- oxidative stress
- cancer therapy
- machine learning
- case report
- early onset
- systemic lupus erythematosus
- risk assessment
- climate change
- replacement therapy
- systemic sclerosis
- combination therapy
- postmenopausal women
- deep learning
- idiopathic pulmonary fibrosis